INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,669,845 | -17.7% | 70,452 | +0.0% | 0.46% | -24.5% |
| Q2 2023 | $4,460,134 | +3.1% | 70,438 | -11.8% | 0.61% | +4.6% |
| Q1 2023 | $4,324,744 | +48.0% | 79,866 | +44.7% | 0.59% | +23.9% |
| Q4 2022 | $2,921,660 | +365.2% | 55,209 | +309.2% | 0.47% | +397.9% |
| Q3 2022 | $628,000 | +193.5% | 13,493 | +116.6% | 0.10% | +630.8% |
| Q4 2019 | $214,000 | -77.9% | 6,229 | -95.2% | 0.01% | -77.6% |
| Q3 2019 | $969,000 | +65.1% | 129,741 | +187.0% | 0.06% | +65.7% |
| Q2 2019 | $587,000 | -75.9% | 45,204 | -60.9% | 0.04% | -57.3% |
| Q1 2018 | $2,435,000 | +25.5% | 115,700 | -13.6% | 0.08% | +46.4% |
| Q4 2017 | $1,940,000 | +81.3% | 133,954 | +97.6% | 0.06% | +60.0% |
| Q3 2017 | $1,070,000 | +10.3% | 67,800 | -13.2% | 0.04% | -10.3% |
| Q2 2017 | $970,000 | -34.5% | 78,100 | -14.3% | 0.04% | -50.0% |
| Q1 2017 | $1,482,000 | +7.5% | 91,184 | -0.2% | 0.08% | -13.3% |
| Q4 2016 | $1,379,000 | – | 91,357 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |